Recent Updates
Recently added Catalysts
FTH Positive Sentiment

Faeth Therapeutics Announces FDA Grant of Fast Track Designation for PIKTOR Plus Paclitaxel in Biomarker-Selected Advanced Endometrial Cancer

Monday, August 17, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Faeth Therapeutics has received Fast Track designation from the FDA for its PIKTOR combination therapy, which includes sapanisertib and serabelisib with paclitaxel. This designation is specifically for treating patients with advanced or recurrent endometrial cancer that have specific genetic alterations. The Fast Track status aims to expedite the development and review process for this promising treatment.

Market Sentiment Analysis

POSITIVE FACTORS

  • FDA granted Fast Track designation for PIKTOR Plus Paclitaxel.
  • Targeted treatment for advanced endometrial cancer patients.
  • Combination therapy aims to improve patient outcomes.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Cash runway
~30 mo
Minimal dilution risk
Lead asset
PAN-301-1
Phase 1 · Prostate Cancer

Full Press Release Details

AUSTIN, Texas--(BUSINESS WIRE)--Faeth Therapeutics (Nasdaq: FTH), a clinical-stage oncology company developing multi-node therapies for cancer patients, including its lead program PIKTOR, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the combination of sapanisertib and serabelisib (PIKTOR) with paclitaxel for the treatment of patients with advanced or recurrent endometrial cancer whose tumors harbor a PI3K/AKT/mTOR pathway alteration and

Frequently Asked Questions

What is the Fast Track designation?

Fast Track designation is an FDA process to expedite the development of drugs for serious conditions.

What is PIKTOR?

PIKTOR is a combination therapy developed by Faeth Therapeutics for cancer treatment.

Which cancer is targeted by PIKTOR?

PIKTOR targets advanced or recurrent endometrial cancer with specific genetic alterations.

What drugs are included in the PIKTOR therapy?

PIKTOR includes sapanisertib and serabelisib combined with paclitaxel.

ShareAdd on Google
Tags: FTH Viatris Investor Conferences Healthcare Faeth Therapeutics PIKTOR Fast Track designation endometrial cancer FDA
Last updated: Aug 17, 2026

Biotech snapshot

Cash runway
$186M liquidity · $6M/mo burn
~30 mo
Minimal dilution risk
Lead asset
PAN-301-1Phase 1
Prostate Cancer →